This article has been corrected. Correction in: Oncotarget. 2018; 9:32273.

Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis

Ling Cao, Yong-Jing Yang, Jian-Dong Diao, Xu-He Zhang, Yan-Ling Liu, Bo-Yu Wang, Zhi-Wen Li and Shi-Xin Liu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:90308-90314. https://doi.org/10.18632/oncotarget.19856

Metrics: PDF 1442 views  |   HTML 2343 views  |   ?  


Ling Cao1,*, Yong-Jing Yang1,*, Jian-Dong Diao2, Xu-He Zhang1, Yan-Ling Liu1, Bo-Yu Wang1, Zhi-Wen Li3 and Shi-Xin Liu1

1Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People’s Republic of China

2Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun 130012, People’s Republic of China

3Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin, 130021, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Shi-Xin Liu, email: [email protected]

Zhi-Wen Li, email: [email protected]

Keywords: zoledronic acid, bone metastasis, dose interval, skeletal-related events, meta-analysis

Received: April 21, 2017     Accepted: July 18, 2017     Published: August 03, 2017


Zoledronic acid is used to treat patients with bone metastasis, but the optimal dosing interval remains controversial. We therefore performed a systematic review and meta-analysis to compare the efficacy and safety of a 12-week interval of zoledronic acid with the standard 4-week interval. Three randomized controlled trials comprising 2650 patients were analyzed. Using a random-effects model, pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. No differences in the occurrence of skeletal-related events (SREs: RR = 0.98; 95% CI = 0.86–1.12; P = 0.80) or grade 3/4 adverse events (RR = 0.91; 95% CI = 0.69–1.20; P = 0.52) were observed between the 12-week and 4-week groups. The 12-week group tended to have lower incidences of osteonecrosis of the jaw [13 (0.98%) vs. 23 (1.73%)] and kidney dysfunction [21 (1.68%) vs. 31 (2.45%)] than the 4-week group, though the difference did not reach statistical significance (RR = 0.58, 95% CI: 0.30–1.12; P = 0.11); (RR = 0.67, 95% CI: 0.39–1.15, P = 0.15). These data show that zoledronic acid administered at 12-week intervals instead of 4-week intervals does not increase the risk of SREs, and may reduce the incidence of osteonecrosis of the jaw and kidney dysfunction. This suggests the 12-week interval with zoledronic acid may be an acceptable treatment option.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19856